A team made up by researchers of the ICO and the University Hospital in Bellvitge has studied the TP53 gene as a factor in the prognostic of the metastases in the liver of a primary colon cancer. In this sense, and after having been operated to extirpate the tumour that has reproduced in the liver, the patients with the mutated TP53 gene have a worse prognostic. The results are based in the widest consecutive series of patients (91 patients) and most homogeneous (they have been operated and treated by the same teams of the Institut Català d’Oncologia and the University Hospital in Bellvitge) of all the studies that have taken place so far. Carcinogenesis: "Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection", published on 27th of January in the on-line edition, and on paper, in the February issue. (Carcinogenesis. Doi: 10.1093/carcin/bgm012).